Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) Stock Competitors & Peer Comparison
See (SRPT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRPT | $17.18 | -8.81% | 2B | -6.70 | -$2.83 | N/A |
| VRTX | $480.10 | -1.50% | 122.6B | 31.54 | $15.31 | N/A |
| REGN | $765.59 | -0.86% | 81.5B | 18.91 | $41.48 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $768.31 | -8.57% | 50.6B | 34.94 | $23.38 | N/A |
| ALNY | $328.07 | -1.44% | 43.4B | 140.50 | $2.33 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $148.66 | -6.28% | 31.7B | -24.01 | -$6.19 | N/A |
| BNTX | $108.89 | -1.80% | 26.4B | -38.68 | -$2.84 | N/A |
| UTHR | $505.88 | +6.85% | 24.2B | 20.29 | $26.37 | N/A |
Stock Comparison
SRPT vs VRTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, VRTX has a market cap of 122.6B. Regarding current trading prices, SRPT is priced at $17.18, while VRTX trades at $480.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas VRTX's P/E ratio is 31.54. In terms of profitability, SRPT's ROE is -0.20%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SRPT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check VRTX's competition here
SRPT vs REGN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, REGN has a market cap of 81.5B. Regarding current trading prices, SRPT is priced at $17.18, while REGN trades at $765.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas REGN's P/E ratio is 18.91. In terms of profitability, SRPT's ROE is -0.20%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SRPT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check REGN's competition here
SRPT vs VRNA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SRPT is priced at $17.18, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SRPT's ROE is -0.20%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check VRNA's competition here
SRPT vs ARGX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ARGX has a market cap of 50.6B. Regarding current trading prices, SRPT is priced at $17.18, while ARGX trades at $768.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ARGX's P/E ratio is 34.94. In terms of profitability, SRPT's ROE is -0.20%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, SRPT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ARGX's competition here
SRPT vs ALNY Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ALNY has a market cap of 43.4B. Regarding current trading prices, SRPT is priced at $17.18, while ALNY trades at $328.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ALNY's P/E ratio is 140.50. In terms of profitability, SRPT's ROE is -0.20%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, SRPT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ALNY's competition here
SRPT vs SGEN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRPT is priced at $17.18, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRPT's ROE is -0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SRPT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check SGEN's competition here
SRPT vs INSM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, INSM has a market cap of 31.7B. Regarding current trading prices, SRPT is priced at $17.18, while INSM trades at $148.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas INSM's P/E ratio is -24.01. In terms of profitability, SRPT's ROE is -0.20%, compared to INSM's ROE of -1.68%. Regarding short-term risk, SRPT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check INSM's competition here
SRPT vs BNTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BNTX has a market cap of 26.4B. Regarding current trading prices, SRPT is priced at $17.18, while BNTX trades at $108.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BNTX's P/E ratio is -38.68. In terms of profitability, SRPT's ROE is -0.20%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, SRPT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BNTX's competition here
SRPT vs UTHR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, UTHR has a market cap of 24.2B. Regarding current trading prices, SRPT is priced at $17.18, while UTHR trades at $505.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas UTHR's P/E ratio is 20.29. In terms of profitability, SRPT's ROE is -0.20%, compared to UTHR's ROE of +0.18%. Regarding short-term risk, SRPT is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check UTHR's competition here
SRPT vs ROIV Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ROIV has a market cap of 20.5B. Regarding current trading prices, SRPT is priced at $17.18, while ROIV trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ROIV's P/E ratio is -24.50. In terms of profitability, SRPT's ROE is -0.20%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, SRPT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ROIV's competition here
SRPT vs BGNE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRPT is priced at $17.18, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRPT's ROE is -0.20%, compared to BGNE's ROE of +0.02%. Regarding short-term risk, SRPT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BGNE's competition here
SRPT vs MRNA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MRNA has a market cap of 20.1B. Regarding current trading prices, SRPT is priced at $17.18, while MRNA trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MRNA's P/E ratio is -7.08. In terms of profitability, SRPT's ROE is -0.20%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MRNA's competition here
SRPT vs RVMD Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RVMD has a market cap of 20B. Regarding current trading prices, SRPT is priced at $17.18, while RVMD trades at $101.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RVMD's P/E ratio is -19.89. In terms of profitability, SRPT's ROE is -0.20%, compared to RVMD's ROE of -0.49%. Regarding short-term risk, SRPT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RVMD's competition here
SRPT vs INCY Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, SRPT is priced at $17.18, while INCY trades at $99.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas INCY's P/E ratio is 15.60. In terms of profitability, SRPT's ROE is -0.20%, compared to INCY's ROE of +0.29%. Regarding short-term risk, SRPT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check INCY's competition here
SRPT vs RPRX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RPRX has a market cap of 19.3B. Regarding current trading prices, SRPT is priced at $17.18, while RPRX trades at $45.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RPRX's P/E ratio is 25.37. In terms of profitability, SRPT's ROE is -0.20%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SRPT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RPRX's competition here
SRPT vs DNA-WT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRPT is priced at $17.18, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRPT's ROE is -0.20%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, SRPT is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check DNA-WT's competition here
SRPT vs GMAB Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, GMAB has a market cap of 18B. Regarding current trading prices, SRPT is priced at $17.18, while GMAB trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas GMAB's P/E ratio is 12.85. In terms of profitability, SRPT's ROE is -0.20%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, SRPT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check GMAB's competition here
SRPT vs ASND Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, SRPT is priced at $17.18, while ASND trades at $225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ASND's P/E ratio is -51.35. In terms of profitability, SRPT's ROE is -0.20%, compared to ASND's ROE of +1.28%. Regarding short-term risk, SRPT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ASND's competition here
SRPT vs IONS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, SRPT is priced at $17.18, while IONS trades at $80.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas IONS's P/E ratio is -50.27. In terms of profitability, SRPT's ROE is -0.20%, compared to IONS's ROE of -0.44%. Regarding short-term risk, SRPT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check IONS's competition here
SRPT vs BBIO Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, SRPT is priced at $17.18, while BBIO trades at $66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BBIO's P/E ratio is -15.81. In terms of profitability, SRPT's ROE is -0.20%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, SRPT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BBIO's competition here
SRPT vs KRTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRPT is priced at $17.18, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRPT's ROE is -0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SRPT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check KRTX's competition here
SRPT vs EXEL Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, EXEL has a market cap of 12B. Regarding current trading prices, SRPT is priced at $17.18, while EXEL trades at $44.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas EXEL's P/E ratio is 16.10. In terms of profitability, SRPT's ROE is -0.20%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, SRPT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check EXEL's competition here
SRPT vs JAZZ Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, JAZZ has a market cap of 12B. Regarding current trading prices, SRPT is priced at $17.18, while JAZZ trades at $190.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas JAZZ's P/E ratio is -31.95. In terms of profitability, SRPT's ROE is -0.20%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, SRPT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check JAZZ's competition here
SRPT vs BMRN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BMRN has a market cap of 11.8B. Regarding current trading prices, SRPT is priced at $17.18, while BMRN trades at $60.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BMRN's P/E ratio is 22.84. In terms of profitability, SRPT's ROE is -0.20%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SRPT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BMRN's competition here
SRPT vs SMMT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, SRPT is priced at $17.18, while SMMT trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas SMMT's P/E ratio is -12.54. In terms of profitability, SRPT's ROE is -0.20%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, SRPT is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check SMMT's competition here
SRPT vs RNA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RNA has a market cap of 11.2B. Regarding current trading prices, SRPT is priced at $17.18, while RNA trades at $72.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RNA's P/E ratio is -17.37. In terms of profitability, SRPT's ROE is -0.20%, compared to RNA's ROE of -0.45%. Regarding short-term risk, SRPT is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RNA's competition here
SRPT vs MDGL Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, SRPT is priced at $17.18, while MDGL trades at $442.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MDGL's P/E ratio is -33.83. In terms of profitability, SRPT's ROE is -0.20%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, SRPT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MDGL's competition here
SRPT vs RXDX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRPT is priced at $17.18, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRPT's ROE is -0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RXDX's competition here
SRPT vs IBRX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, IBRX has a market cap of 9.4B. Regarding current trading prices, SRPT is priced at $17.18, while IBRX trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas IBRX's P/E ratio is -23.27. In terms of profitability, SRPT's ROE is -0.20%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, SRPT is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check IBRX's competition here
SRPT vs TECH Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, SRPT is priced at $17.18, while TECH trades at $56.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas TECH's P/E ratio is 109.19. In terms of profitability, SRPT's ROE is -0.20%, compared to TECH's ROE of +0.04%. Regarding short-term risk, SRPT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check TECH's competition here
SRPT vs PCVX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, PCVX has a market cap of 9B. Regarding current trading prices, SRPT is priced at $17.18, while PCVX trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas PCVX's P/E ratio is -13.01. In terms of profitability, SRPT's ROE is -0.20%, compared to PCVX's ROE of -0.22%. Regarding short-term risk, SRPT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check PCVX's competition here
SRPT vs IMGN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRPT is priced at $17.18, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRPT's ROE is -0.20%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SRPT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check IMGN's competition here
SRPT vs ARWR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ARWR has a market cap of 8.6B. Regarding current trading prices, SRPT is priced at $17.18, while ARWR trades at $62.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ARWR's P/E ratio is 38.51. In terms of profitability, SRPT's ROE is -0.20%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, SRPT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ARWR's competition here
SRPT vs BPMC Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SRPT is priced at $17.18, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SRPT's ROE is -0.20%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, SRPT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BPMC's competition here
SRPT vs AXSM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, AXSM has a market cap of 8.3B. Regarding current trading prices, SRPT is priced at $17.18, while AXSM trades at $162.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas AXSM's P/E ratio is -35.16. In terms of profitability, SRPT's ROE is -0.20%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, SRPT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check AXSM's competition here
SRPT vs HALO Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, SRPT is priced at $17.18, while HALO trades at $68.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas HALO's P/E ratio is 14.84. In terms of profitability, SRPT's ROE is -0.20%, compared to HALO's ROE of +0.93%. Regarding short-term risk, SRPT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check HALO's competition here
SRPT vs CERE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRPT is priced at $17.18, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRPT's ROE is -0.20%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SRPT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CERE's competition here
SRPT vs ABVX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ABVX has a market cap of 8.1B. Regarding current trading prices, SRPT is priced at $17.18, while ABVX trades at $119.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ABVX's P/E ratio is -23.40. In terms of profitability, SRPT's ROE is -0.20%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, SRPT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ABVX's competition here
SRPT vs KRYS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, SRPT is priced at $17.18, while KRYS trades at $274.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas KRYS's P/E ratio is 40.79. In terms of profitability, SRPT's ROE is -0.20%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SRPT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check KRYS's competition here
SRPT vs CYTK Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, SRPT is priced at $17.18, while CYTK trades at $62.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CYTK's P/E ratio is -9.98. In terms of profitability, SRPT's ROE is -0.20%, compared to CYTK's ROE of +2.33%. Regarding short-term risk, SRPT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CYTK's competition here
SRPT vs NUVL Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, NUVL has a market cap of 7.6B. Regarding current trading prices, SRPT is priced at $17.18, while NUVL trades at $102.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas NUVL's P/E ratio is -19.61. In terms of profitability, SRPT's ROE is -0.20%, compared to NUVL's ROE of -0.39%. Regarding short-term risk, SRPT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check NUVL's competition here
SRPT vs MTSR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SRPT is priced at $17.18, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SRPT's ROE is -0.20%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, SRPT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MTSR's competition here
SRPT vs PRAX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, SRPT is priced at $17.18, while PRAX trades at $338.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas PRAX's P/E ratio is -26.76. In terms of profitability, SRPT's ROE is -0.20%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, SRPT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check PRAX's competition here
SRPT vs KYMR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, SRPT is priced at $17.18, while KYMR trades at $91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas KYMR's P/E ratio is -25.19. In terms of profitability, SRPT's ROE is -0.20%, compared to KYMR's ROE of -0.33%. Regarding short-term risk, SRPT is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check KYMR's competition here
SRPT vs MRUS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SRPT is priced at $17.18, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SRPT's ROE is -0.20%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, SRPT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MRUS's competition here
SRPT vs RYTM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $17.18, while RYTM trades at $98.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RYTM's P/E ratio is -31.98. In terms of profitability, SRPT's ROE is -0.20%, compared to RYTM's ROE of -1.66%. Regarding short-term risk, SRPT is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check RYTM's competition here
SRPT vs ACLX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $17.18, while ACLX trades at $113.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ACLX's P/E ratio is -29.02. In terms of profitability, SRPT's ROE is -0.20%, compared to ACLX's ROE of -0.51%. Regarding short-term risk, SRPT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ACLX's competition here
SRPT vs RETA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $17.18, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRPT's ROE is -0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRPT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RETA's competition here
SRPT vs BLTE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $17.18, while BLTE trades at $189.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BLTE's P/E ratio is -97.94. In terms of profitability, SRPT's ROE is -0.20%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, SRPT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BLTE's competition here
SRPT vs COGT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, COGT has a market cap of 6.1B. Regarding current trading prices, SRPT is priced at $17.18, while COGT trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas COGT's P/E ratio is -19.50. In terms of profitability, SRPT's ROE is -0.20%, compared to COGT's ROE of -1.00%. Regarding short-term risk, SRPT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check COGT's competition here
SRPT vs MIRM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, SRPT is priced at $17.18, while MIRM trades at $94.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MIRM's P/E ratio is -129.31. In terms of profitability, SRPT's ROE is -0.20%, compared to MIRM's ROE of -0.16%. Regarding short-term risk, SRPT is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check MIRM's competition here
SRPT vs CDTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SRPT is priced at $17.18, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SRPT's ROE is -0.20%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, SRPT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CDTX's competition here
SRPT vs IMVT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $17.18, while IMVT trades at $27.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas IMVT's P/E ratio is -10.20. In terms of profitability, SRPT's ROE is -0.20%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, SRPT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check IMVT's competition here
SRPT vs ABCM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $17.18, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRPT's ROE is -0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRPT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ABCM's competition here
SRPT vs ISEE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $17.18, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRPT's ROE is -0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRPT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ISEE's competition here
SRPT vs PTGX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, PTGX has a market cap of 5.4B. Regarding current trading prices, SRPT is priced at $17.18, while PTGX trades at $87.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas PTGX's P/E ratio is 131.97. In terms of profitability, SRPT's ROE is -0.20%, compared to PTGX's ROE of +0.07%. Regarding short-term risk, SRPT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check PTGX's competition here
SRPT vs PTCT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, SRPT is priced at $17.18, while PTCT trades at $67.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas PTCT's P/E ratio is 7.88. In terms of profitability, SRPT's ROE is -0.20%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, SRPT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check PTCT's competition here
SRPT vs CRSP Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, SRPT is priced at $17.18, while CRSP trades at $59.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CRSP's P/E ratio is -8.53. In terms of profitability, SRPT's ROE is -0.20%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, SRPT is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check CRSP's competition here
SRPT vs FBIOX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, SRPT is priced at $17.18, while FBIOX trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas FBIOX's P/E ratio is N/A. In terms of profitability, SRPT's ROE is -0.20%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, SRPT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check FBIOX's competition here
SRPT vs CAI Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, SRPT is priced at $17.18, while CAI trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CAI's P/E ratio is -5.21. In terms of profitability, SRPT's ROE is -0.20%, compared to CAI's ROE of +0.27%. Regarding short-term risk, SRPT is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CAI's competition here
SRPT vs ALKS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ALKS has a market cap of 5.1B. Regarding current trading prices, SRPT is priced at $17.18, while ALKS trades at $30.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ALKS's P/E ratio is 15.44. In terms of profitability, SRPT's ROE is -0.20%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, SRPT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ALKS's competition here
SRPT vs CELC Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CELC has a market cap of 5B. Regarding current trading prices, SRPT is priced at $17.18, while CELC trades at $109.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CELC's P/E ratio is -29.02. In terms of profitability, SRPT's ROE is -0.20%, compared to CELC's ROE of -1.79%. Regarding short-term risk, SRPT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CELC's competition here
SRPT vs SRRK Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, SRRK has a market cap of 4.8B. Regarding current trading prices, SRPT is priced at $17.18, while SRRK trades at $44.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas SRRK's P/E ratio is -14.91. In terms of profitability, SRPT's ROE is -0.20%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, SRPT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check SRRK's competition here
SRPT vs TGTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, SRPT is priced at $17.18, while TGTX trades at $30.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas TGTX's P/E ratio is 10.71. In terms of profitability, SRPT's ROE is -0.20%, compared to TGTX's ROE of +1.33%. Regarding short-term risk, SRPT is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check TGTX's competition here
SRPT vs CGON Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CGON has a market cap of 4.6B. Regarding current trading prices, SRPT is priced at $17.18, while CGON trades at $56.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CGON's P/E ratio is -27.80. In terms of profitability, SRPT's ROE is -0.20%, compared to CGON's ROE of -0.22%. Regarding short-term risk, SRPT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CGON's competition here
SRPT vs AKRO Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SRPT is priced at $17.18, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SRPT's ROE is -0.20%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check AKRO's competition here
SRPT vs FOLD Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SRPT is priced at $17.18, while FOLD trades at $14.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas FOLD's P/E ratio is -358.50. In terms of profitability, SRPT's ROE is -0.20%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SRPT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check FOLD's competition here
SRPT vs ALPN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRPT is priced at $17.18, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRPT's ROE is -0.20%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SRPT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ALPN's competition here
SRPT vs CRNX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CRNX has a market cap of 4.4B. Regarding current trading prices, SRPT is priced at $17.18, while CRNX trades at $42.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CRNX's P/E ratio is -9.58. In terms of profitability, SRPT's ROE is -0.20%, compared to CRNX's ROE of -0.35%. Regarding short-term risk, SRPT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CRNX's competition here
SRPT vs OPT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRPT is priced at $17.18, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRPT's ROE is -0.20%, compared to OPT's ROE of +0.88%. Regarding short-term risk, SRPT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check OPT's competition here
SRPT vs ACAD Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, SRPT is priced at $17.18, while ACAD trades at $24.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ACAD's P/E ratio is 16.11. In terms of profitability, SRPT's ROE is -0.20%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, SRPT is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check ACAD's competition here
SRPT vs ERAS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, SRPT is priced at $17.18, while ERAS trades at $13.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ERAS's P/E ratio is -31.30. In terms of profitability, SRPT's ROE is -0.20%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, SRPT is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ERAS's competition here
SRPT vs MRTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRPT is priced at $17.18, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRPT's ROE is -0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SRPT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MRTX's competition here
SRPT vs NAMS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, SRPT is priced at $17.18, while NAMS trades at $34.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas NAMS's P/E ratio is -20.35. In terms of profitability, SRPT's ROE is -0.20%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, SRPT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check NAMS's competition here
SRPT vs APGE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, APGE has a market cap of 3.9B. Regarding current trading prices, SRPT is priced at $17.18, while APGE trades at $68.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas APGE's P/E ratio is -16.18. In terms of profitability, SRPT's ROE is -0.20%, compared to APGE's ROE of -0.39%. Regarding short-term risk, SRPT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check APGE's competition here
SRPT vs GPCR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, GPCR has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $17.18, while GPCR trades at $64.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas GPCR's P/E ratio is -18.18. In terms of profitability, SRPT's ROE is -0.20%, compared to GPCR's ROE of -0.26%. Regarding short-term risk, SRPT is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check GPCR's competition here
SRPT vs VKTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $17.18, while VKTX trades at $32.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas VKTX's P/E ratio is -10.38. In terms of profitability, SRPT's ROE is -0.20%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, SRPT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check VKTX's competition here
SRPT vs CORT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $17.18, while CORT trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CORT's P/E ratio is 41.63. In terms of profitability, SRPT's ROE is -0.20%, compared to CORT's ROE of +0.16%. Regarding short-term risk, SRPT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CORT's competition here
SRPT vs LGND Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, LGND has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $17.18, while LGND trades at $196.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas LGND's P/E ratio is 84.31. In terms of profitability, SRPT's ROE is -0.20%, compared to LGND's ROE of +0.06%. Regarding short-term risk, SRPT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check LGND's competition here
SRPT vs RYZB Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $17.18, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRPT's ROE is -0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRPT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check RYZB's competition here
SRPT vs ADMA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ADMA has a market cap of 3.7B. Regarding current trading prices, SRPT is priced at $17.18, while ADMA trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ADMA's P/E ratio is 18.23. In terms of profitability, SRPT's ROE is -0.20%, compared to ADMA's ROE of +0.54%. Regarding short-term risk, SRPT is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.Check ADMA's competition here
SRPT vs CBAY Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRPT is priced at $17.18, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRPT's ROE is -0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SRPT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CBAY's competition here
SRPT vs TERN Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, TERN has a market cap of 3.7B. Regarding current trading prices, SRPT is priced at $17.18, while TERN trades at $39.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas TERN's P/E ratio is -40.57. In terms of profitability, SRPT's ROE is -0.20%, compared to TERN's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check TERN's competition here
SRPT vs CNTA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, SRPT is priced at $17.18, while CNTA trades at $26.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CNTA's P/E ratio is -14.27. In terms of profitability, SRPT's ROE is -0.20%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, SRPT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CNTA's competition here
SRPT vs SWTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRPT is priced at $17.18, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SRPT's ROE is -0.20%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, SRPT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check SWTX's competition here
SRPT vs DNLI Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, DNLI has a market cap of 3.5B. Regarding current trading prices, SRPT is priced at $17.18, while DNLI trades at $21.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas DNLI's P/E ratio is -7.64. In terms of profitability, SRPT's ROE is -0.20%, compared to DNLI's ROE of -0.46%. Regarding short-term risk, SRPT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check DNLI's competition here
SRPT vs XENE Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, XENE has a market cap of 3.4B. Regarding current trading prices, SRPT is priced at $17.18, while XENE trades at $44.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas XENE's P/E ratio is -11.46. In terms of profitability, SRPT's ROE is -0.20%, compared to XENE's ROE of -0.46%. Regarding short-term risk, SRPT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check XENE's competition here
SRPT vs ARQT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ARQT has a market cap of 3.3B. Regarding current trading prices, SRPT is priced at $17.18, while ARQT trades at $27.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ARQT's P/E ratio is -79.44. In terms of profitability, SRPT's ROE is -0.20%, compared to ARQT's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ARQT's competition here
SRPT vs EWTX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, SRPT is priced at $17.18, while EWTX trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas EWTX's P/E ratio is -19.19. In terms of profitability, SRPT's ROE is -0.20%, compared to EWTX's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check EWTX's competition here
SRPT vs KNSA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, KNSA has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $17.18, while KNSA trades at $43.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas KNSA's P/E ratio is 95.02. In terms of profitability, SRPT's ROE is -0.20%, compared to KNSA's ROE of +0.07%. Regarding short-term risk, SRPT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check KNSA's competition here
SRPT vs TARS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, TARS has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $17.18, while TARS trades at $75.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas TARS's P/E ratio is -36.51. In terms of profitability, SRPT's ROE is -0.20%, compared to TARS's ROE of -0.20%. Regarding short-term risk, SRPT is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check TARS's competition here
SRPT vs ALMS Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $17.18, while ALMS trades at $28.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas ALMS's P/E ratio is -13.67. In terms of profitability, SRPT's ROE is -0.20%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, SRPT is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check ALMS's competition here
SRPT vs CPRX Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $17.18, while CPRX trades at $24.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas CPRX's P/E ratio is 14.54. In terms of profitability, SRPT's ROE is -0.20%, compared to CPRX's ROE of +0.26%. Regarding short-term risk, SRPT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check CPRX's competition here
SRPT vs BEAM Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, SRPT is priced at $17.18, while BEAM trades at $28.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas BEAM's P/E ratio is -6.71. In terms of profitability, SRPT's ROE is -0.20%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, SRPT is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check BEAM's competition here
SRPT vs NAMSW Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, NAMSW has a market cap of 3B. Regarding current trading prices, SRPT is priced at $17.18, while NAMSW trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SRPT's ROE is -0.20%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, SRPT is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check NAMSW's competition here
SRPT vs VERA Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $17.18, while VERA trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas VERA's P/E ratio is -10.45. In terms of profitability, SRPT's ROE is -0.20%, compared to VERA's ROE of -0.51%. Regarding short-term risk, SRPT is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check VERA's competition here
SRPT vs MORF Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $17.18, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MORF's P/E ratio is -14.88. In terms of profitability, SRPT's ROE is -0.20%, compared to MORF's ROE of -0.29%. Regarding short-term risk, SRPT is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MORF's competition here
SRPT vs MOR Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $17.18, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas MOR's P/E ratio is -12.64. In terms of profitability, SRPT's ROE is -0.20%, compared to MOR's ROE of -1.84%. Regarding short-term risk, SRPT is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check MOR's competition here
SRPT vs VCYT Comparison February 2026
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2B. In comparison, VCYT has a market cap of 2.8B. Regarding current trading prices, SRPT is priced at $17.18, while VCYT trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -6.70, whereas VCYT's P/E ratio is 94.00. In terms of profitability, SRPT's ROE is -0.20%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SRPT is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.Check VCYT's competition here